Please check your internet connection and try again.
# Tabgenixim (Cefixime)
## Overview
Tabgenixim is a brand name for **Cefixime**, a third-generation cephalosporin antibiotic. It acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), resulting in bactericidal activity. It possesses enhanced stability against many beta-lactamases compared to first- or second-generation cephalosporins.
## Primary Indications
* Acute otitis media
* Pharyngitis and tonsillitis
* Acute exacerbations of chronic bronchitis
* Uncomplicated urinary tract infections (UTIs)
* Uncomplicated gonorrhea (cervical, urethral, and rectal)
## Adult Dosing
* **General infections:** 400 mg daily, administered as a single dose or in two divided doses of 200 mg every 12 hours.
* **Uncomplicated gonorrhea:** 400 mg as a single oral dose.
## Pediatric Dosing
* **Children (>6 months):** 8 mg/kg/day administered as a single daily dose or in two divided doses (4 mg/kg every 12 hours).
* **Max Pediatric Dose:** 400 mg/day.
## Dose Adjustments
* **Renal Impairment:**
* CrCl 21–60 mL/min: Administer 75% of the standard dose.
* CrCl <20 mL/min: Administer 50% of the standard dose.
* **Hepatic Impairment:** No specific recommendations provided by the manufacturer; use caution.
## Contraindications
* Hypersensitivity to cefixime or any component of the formulation.
* History of severe allergic reactions (e.g., anaphylaxis) to penicillins or other beta-lactam antibiotics.
## Adverse Effects
* **Common:** Diarrhea (frequently dose-related), abdominal pain, nausea, dyspepsia, and flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypersensitivity reactions (rash, urticaria, serum sickness), and rare hematologic abnormalities (thrombocytopenia, leukopenia).
## Key Drug Interactions
* **Warfarin/Anticoagulants:** May enhance the anticoagulant effect of vitamin K antagonists. Monitor INR closely.
* **Probenecid:** May increase serum levels and systemic exposure of cefixime by inhibiting renal excretion.
* **Vaccines (Live/Attenuated):** Potential to diminish the therapeutic effect of the live typhoid vaccine.
## Monitoring
* Monitor for signs of hypersensitivity.
* Monitor for persistent diarrhea or signs of *C. difficile* infection.
* In patients on long-term therapy, assess renal and hepatic function, and perform periodic CBCs.
## Clinical Pearls
* Cefixime provides poor activity against *Staphylococcus aureus*.
* The suspension form and tablet form are **not** bioequivalent; do not substitute milligram-for-milligram without adjusting for formulation differences if specified by the manufacturer.
* Ensure patients complete the full course of therapy even if symptoms improve.
* Dosing for specific MDR (multidrug-resistant) organisms or severe infections may vary significantly by local institutional antibiograms or infectious disease guidelines.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and prescribing information change frequently. Always verify specific dosing, safety precautions, and patient-specific contraindications via professional drug databases (e.g., Lexicomp, UpToDate) or the official FDA-approved package insert before prescribing or administering medication.
